Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Obesity-driven inflammation enables triple-negative breast cancer progression through immunosuppression [scRNA-Seq]

ABSTRACT: control and obese, C57BL6J mice with or without sulindac treatment were injected with E0771 cells and tumor growth was monitored

ORGANISM(S): Mus musculus

PROVIDER: GSE294999 | GEO | 2025/12/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Obesity-driven inflammation enables triple-negative breast cancer progression through immunosuppression

Project description:control and obese, C57BL6J mice with or without sulindac treatment were injected with E0771, metMWntlung, or metMWntliver cells and tumor growth was monitored

2025-12-02 | GSE294944 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-Study2_tumor

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via vertical sleeve gastrectomy or calorie restriction were injected with E0771 cells and tumor growth was monitored

2023-09-12 | GSE230471 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-RRBS

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via low-fat diet or verticle sleeve gastrectomy were injected with E0771 cells and tumor growth was monitored

2023-09-12 | GSE230473 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-RNAseq

2023-09-12 | GSE230472 | GEO

Calorie Restriction Outperforms Bariatric Surgery in Reversing Obesity-Driven Tumor Progression in a Mouse Model of Triple Negative Breast Cancer-Study1_tumor

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via vertical sleeve gastrectomy or low fat diet were injected with E0771 cells and tumor growth was monitored

2023-09-12 | GSE230470 | GEO

Various forms of calorie restriction, but not a nonrestricted low-fat diet, reverse obesity-associated tumor growth and lung metastasis in a mouse model of triple-negative breast cancer-RRBS

Project description:lean control, obese, and formerly obese C57BL6N mice which underwent weight loss via low-fat diet or various forms of calory restriction were injected with E0771 cells and tumor growth was monitored

2022-05-12 | GSE202331 | GEO

Various forms of calorie restriction, but not a nonrestricted low-fat diet, reverse obesity-associated tumor growth and lung metastasis in a mouse model of triple-negative breast cancer-RNAseq

2022-05-12 | GSE202330 | GEO

Various forms of calorie restriction, but not a nonrestricted low-fat diet, reverse obesity-associated tumor growth and lung metastasis in a mouse model of triple-negative breast cancer (microarray)

2025-02-04 | GSE272329 | GEO

Age and obesity associated immune dysfunction mammary tumor growth

Project description:lean control, obese (DIO), aged 6 (young) or 18months (Aged) C57BL6N mice which underwent weight loss via intermittent calory restriction (ICR) or not (ad lib) were injected with E0771 cells and tumor growth was monitored

2025-02-04 | GSE272326 | GEO

Expression data from murine colon tumors induced by azoxymethane. Tumors from control, obese, formerly obese, or sulindac-treated mice.

Project description:Obesity is associated with an increased risk of colon cancer. Our current study examines whether weight loss and/or treatment with the non-steroidal anti-inflammatory drug (NSAID) sulindac suppresses the protumor effects of obesity in a mouse model of colon cancer. Azoxymethane-treated male FVB/N mice were fed a low-fat diet (LFD) or high-fat diet (HFD) for 15 weeks, then HFD mice were randomized to remain on HFD (obese) or switch to LFD (formerly obese (FOb-LFD)). Within the control (LFD), obese, and FOb-LFD groups, half the mice were also randomized to start sulindac treatment (140 ppm in the diet). All mice were euthanized seven weeks later. FOb-LFD mice had intermediate levels of body weight, lower than obese but higher than control mice (P<0.05). Sulindac did not affect body weight. Obese mice had greater tumor multiplicity and burden than all other groups (P<0.05). Transcriptomic profiling indicated that both weight loss and sulindac modulate the expression of tumor genes related to invasion and may promote a more anti-tumor immune landscape. Furthermore, the fecal microbes Prevotella and Akkermansia muciniphila, both known to be elevated in colorectal cancer patients, were positively correlated with tumor multiplicity and reduced by sulindac in obese mice. In sum, either moderate weight loss or sulindac treatment completely reversed the effects of chronic obesity on colon tumorigenesis. Our findings suggest that an investigation regarding the effects of NSAID treatment on colon cancer risk and/or progression in obese individuals is warranted, particularly for those unable to achieve moderate weight loss.

2022-08-10 | GSE197846 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data